EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficient correction of ABCA4 variants by CRISPR-Cas9 in hiPSCs derived from Stargardt disease patients

Laura Siles, Sheila Ruiz-Nogales, Arnau Navinés-Ferrer, Pilar Méndez-Vendrell, Esther Pomares

Molecular Therapy - Nucleic Acids · 2023-06 · 32 · 64-79

DOI: 10.1016/j.omtn.2023.02.032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy - Nucleic Acids, 2023-06. Verfasst von Laura Siles und 4 weiteren Autor:innen. Beteiligte Einrichtung: Fundació de Recerca de l'Institut de Microcirurgia Ocular, 08035 Barcelona, Spain. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inherited retinal dystrophies comprise a broad group of genetic eye diseases without effective treatment. Among them, Stargardt disease is the second most prevalent pathology. This pathology triggers progressive retinal degeneration and vision loss in children and adults. In recent years, the evolution of several genome editing technologies, such as the CRISPR-Cas9 system, has revolutionized disease modeling and personalized medicine. Human induced pluripotent stem cells also provide a valuable tool for in vitro disease studies and therapeutic applications. Here, we show precise correction of two ABCA4 pathogenic variants in human induced pluripotent stem cells from two unrelated patients affected with Stargardt disease. Gene editing was achieved with no detectable off-target genomic alterations, demonstrating efficient ABCA4 gene correction without deleterious effects. These results will contribute to the development of emerging gene and cell therapies for inherited retinal dystrophies.

Schlagwörter

Stichwörter der Autor:innen

ABCA4 geneCRISPR-Cas9MT: RNA/DNA EditingStargardt diseasegene editinghuman induced pluripotent stem cellsinherited retinal dystrophies

Autor:innen und Institutionen

  • Fundació de Recerca de l'Institut de Microcirurgia Ocular, 08035 Barcelona, Spain.
  • Departament de Genètica, Institut de Microcirurgia Ocular, IMO Grupo Miranza, 08035 Barcelona, Spain.

Zitieren

APA

Siles, L., Ruiz-Nogales, S., Navinés-Ferrer, A., Méndez-Vendrell, P., & Pomares, E. (2023). Efficient correction of ABCA4 variants by CRISPR-Cas9 in hiPSCs derived from Stargardt disease patients. Molecular Therapy - Nucleic Acids, 32, 64-79. https://doi.org/10.1016/j.omtn.2023.02.032

Vancouver

Siles L, Ruiz-Nogales S, Navinés-Ferrer A, Méndez-Vendrell P, Pomares E. Efficient correction of ABCA4 variants by CRISPR-Cas9 in hiPSCs derived from Stargardt disease patients. Molecular Therapy - Nucleic Acids. 2023;32:64-79. doi:10.1016/j.omtn.2023.02.032

BibTeX
@article{Siles2023,
  author = {Siles, Laura and Ruiz-Nogales, Sheila and Navinés-Ferrer, Arnau and Méndez-Vendrell, Pilar and Pomares, Esther},
  title = {Efficient correction of ABCA4 variants by CRISPR-Cas9 in hiPSCs derived from Stargardt disease patients},
  journal = {Molecular Therapy - Nucleic Acids},
  year = {2023},
  volume = {32},
  pages = {64--79},
  doi = {10.1016/j.omtn.2023.02.032}
}
Kostenlos starten →